Key result
Secretin receptor knockout blunts angiotensin II-induced albuminuria and renal transporter upregulation in mice.
Why the study?
Secretin signaling affects AVP and aldosterone release and its receptor functionally interacts with the angiotensin II receptor, but how loss of secretin signaling alters renin-angiotensin-aldosterone system activation and its cardiovascular and renal consequences was unclear.
Does loss of secretin receptor signaling alter the cardiovascular and renal consequences of continuous angiotensin II infusion in mice?
Does loss of secretin receptor signaling alter the cardiovascular and renal consequences of continuous angiotensin II infusion in mice?
Defective secretin signaling in SCTR knockout mice blunts the renal effects of chronic angiotensin II infusion, highlighting a functional role for the secretin receptor in renin-angiotensin-aldosterone system activation.
Answers are grounded in this paper and cite their sources.
Secretin-RAAS interactions merit exploration in renal models; leaves open any clinical role in hypertension or acid-base disorders.
Background The renin-angiotensin-aldosterone system is activated through several different pathways in response to loss of circulatory volume. Activation increases renal electrolyte and water reabsorption along with bicarbonate excretion mediated through the Cl-/HCO3- antiporter pendrin. Secretin, a hormone typically associated with the gastrointestinal system, also increases pendrin-dependent base excretion. Additional evidence suggests that secretin signaling affects both AVP and aldosterone release and that the secretin receptor (SCTR) and angiotensin II receptor interact functionally. This study aimed to investigate how loss of secretin signaling alters the activation of the renin-angiotensin-aldosterone system and the cardiovascular and renal consequences hereof. Methods Following cardiovascular and renal phenotyping, SCTR WT and KO mice (10+10, C57BL/6 background) were subjected to continuous angiotensin II infusion via mini-osmotic pumps (750 ng/kg/min) for 28 days. At termination, similar phenotyping was repeated. The mice were then anesthetized (i.p. ketamine/xylazine) and kidney tissue and plasma harvested. Western blots for relevant transporters were performed on kidney lysates. Additionally, fibrosis staining and immunohistochemistry were performed on the harvested tissue. Results Angiotensin II induced marked hypertension in both KO and WT mice and decreased GFR. WTs developed significantly more albuminuria. Urinary pH increased significantly in WTs while no effect was seen in the KOs. WTs had significantly higher fractional sodium excretion than KOs. Furthermore, WTs had a greater upregulation of both ENaC and pendrin protein levels compared with KOs, while both genotypes exhibited increased NCC activation. Further analyses of aldosterone levels and ADH activation are pending. Conclusion Defective secretin signaling in SCTR KO mice blunts the systemic and renal effects of angiotensin II. Together, these data expand on the importance of functional secretin signaling in the activation of the renin-angiotensin-aldosterone system.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2026) studied Angiotensin II-induced hypertension (n=20). Secretin receptor (SCTR) knockout with continuous angiotensin II infusion vs. Secretin receptor wild-type (WT) mice receiving continuous angiotensin II infusion (750 ng/kg/min) was evaluated on Cardiovascular and renal consequences of RAAS activation (blood pressure, GFR, albuminuria, urinary pH, fractional sodium excretion, and renal transporter protein expression).
Synapse has enriched 10 related papers. Consider them for comparative context: